Kymab, a Cambridge, UK-based antibodies-to-medicines company, has announced the appointment of Dr David Chiswell OBE as Chief Executive, with effect from next month.
Chiswell has been interim CEO of the firm since early 2015 having been appointed Chairman in September 2013. He will step down from this role and Dr Tim Rink will become Lead Director with effect from April.
Chiswell has more than 30 years’ experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002. CAT listed on the London Stock Exchange in April 1997 and Nasdaq in June 2001, and was subsequently sold to AstraZeneca where it is part of its biopharmaceutical franchise.
Since leaving CAT in 2002, Chiswell has focused on the development of early-stage biotechnology companies, having previously been a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and CEO of Nabriva Therapeutics (2009 to 2012). Chiswell is currently Chairman of Albireo Pharma and a Director of Nabriva Therapeutics.
He is a past chairman of the UK BioIndustry Association (BIA) and in 2006 he was awarded an OBE for services to the biotechnology industry.
